{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:39:15Z","timestamp":1785163155914,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K15767"],"award-info":[{"award-number":["JP24K15767"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12149-025-02146-0","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T07:11:40Z","timestamp":1766214700000},"page":"425-433","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative evaluation of CortexID and VIZCalc software in brain amyloid PET: a retrospective study of 116 cases"],"prefix":"10.1007","volume":"40","author":[{"given":"Manduukhai","family":"Badarchin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8960-3662","authenticated-orcid":false,"given":"Yoichi","family":"Otomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Shinya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Takaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyasu","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Tomioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Nakataki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuishin","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Numata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"issue":"3","key":"2146_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306\u201319. https:\/\/doi.org\/10.1002\/ana.20009.","journal-title":"Ann Neurol"},{"issue":"4","key":"2146_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2146_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1212\/CON.0000000000000700","volume":"25","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD. Late-onset alzheimer disease. Continuum (Minneap Minn). 2019;25(1):14\u201333. https:\/\/doi.org\/10.1212\/CON.0000000000000700.","journal-title":"Continuum (Minneap Minn)"},{"issue":"7","key":"2146_CR4","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2967\/jnumed.113.127068","volume":"54","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. J Nucl Med. 2013;54(7):1011\u20133. https:\/\/doi.org\/10.2967\/jnumed.113.127068.","journal-title":"J Nucl Med"},{"issue":"1","key":"2146_CR5","doi-asserted-by":"publisher","first-page":"e14338","DOI":"10.1002\/alz.14338","volume":"21","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, et al. Updated appropriate use criteria for amyloid and Tau PET: A report from the alzheimer\u2019s association and society for nuclear medicine and molecular imaging workgroup. Alzheimers Dement. 2025;21(1):e14338. https:\/\/doi.org\/10.1002\/alz.14338.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2146_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13550-023-00994-3","volume":"13","author":"HG Pemberton","year":"2023","unstructured":"Pemberton HG, Buckley C, Battle M, Bollack A, Patel V, Tomova P, et al. Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment. EJNMMI Res. 2023;13(1):48. https:\/\/doi.org\/10.1186\/s13550-023-00994-3.","journal-title":"EJNMMI Res"},{"issue":"8","key":"2146_CR7","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of alzheimer\u2019s disease: alzheimer\u2019s association workgroup. Alzheimers Dement. 2024;20(8):5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"2146_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jalz.2019.02.005","volume":"15","author":"V Dor\u00e9","year":"2019","unstructured":"Dor\u00e9 V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O, et al. Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL\u00ae approaches: validation against histopathology. Alzheimers Dement. 2019;15(6):807\u201316. https:\/\/doi.org\/10.1016\/j.jalz.2019.02.005.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2146_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, et al. Multisite study of the relationships between antemortem [11\u00a0C]PIB-PET centiloid values and postmortem measures of alzheimer\u2019s disease neuropathology. Alzheimers Dement. 2019;15(2):205\u201316. https:\/\/doi.org\/10.1016\/j.jalz.2018.09.001.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2146_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13195-020-00587-5","volume":"12","author":"S Amadoru","year":"2020","unstructured":"Amadoru S, Dor\u00e9 V, McLean CA, Hinton F, Shepherd CE, Halliday GM, et al. Comparison of amyloid PET measured in centiloid units with neuropathological findings in alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12(1):22. https:\/\/doi.org\/10.1186\/s13195-020-00587-5.","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"2146_CR11","doi-asserted-by":"publisher","first-page":"e662","DOI":"10.1212\/WNL.0000000000011222","volume":"96","author":"LM van der Kall","year":"2021","unstructured":"van der Kall LM, Truong T, Burnham SC, Dor\u00e9 V, Mulligan RS, Bozinovski S, et al. Association of \u03b2-Amyloid Level, clinical Progression, and longitudinal cognitive change in normal older individuals. Neurology. 2021;96(5):e662\u201370. https:\/\/doi.org\/10.1212\/WNL.0000000000011222.","journal-title":"Neurology"},{"issue":"1","key":"2146_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s00259-020-04942-4","volume":"48","author":"BJ Hanseeuw","year":"2021","unstructured":"Hanseeuw BJ, Malotaux V, Dicot L, Quenon L, Sznajer Y, Cerman J, et al. Defining a centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study. Eur J Nucl Med Mol Imaging. 2021;48(1):302\u201310. https:\/\/doi.org\/10.1007\/s00259-020-04942-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2146_CR13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.21037\/qims-21-188","volume":"12","author":"EG M\u00fcller","year":"2022","unstructured":"M\u00fcller EG, Stokke C, Stokmo HL, Edwin TH, Knapskog AB, Revheim ME. Evaluation of semi-quantitative measures of 18F-flutemetamol PET for the clinical diagnosis of alzheimer\u2019s disease. Quant Imaging Med Surg. 2022;12(1):493\u2013509. https:\/\/doi.org\/10.21037\/qims-21-188.","journal-title":"Quant Imaging Med Surg"},{"issue":"1","key":"2146_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Sr, Jagust WJ, et al. The centiloid project: standardizing quantitative amyloid plaque Estimation by PET. Alzheimers Dement. 2015;11(1):1\u2013e151. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"2146_CR15","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1136\/jnnp-2012-302548","volume":"83","author":"DA Wolk","year":"2012","unstructured":"Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in alzheimer\u2019s disease: comparison of Florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012;83(9):923\u20136. https:\/\/doi.org\/10.1136\/jnnp-2012-302548.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2146_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ana.22068","volume":"68","author":"R Vandenberghe","year":"2010","unstructured":"Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319\u201329. https:\/\/doi.org\/10.1002\/ana.22068.","journal-title":"Ann Neurol"},{"issue":"6","key":"2146_CR17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00259-012-2088-x","volume":"39","author":"VL Villemagne","year":"2012","unstructured":"Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O\u2019Keefe G, et al. Comparison of 11\u00a0C-PiB and 18F-florbetaben for A\u03b2 imaging in ageing and alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2012;39(6):983\u20139. https:\/\/doi.org\/10.1007\/s00259-012-2088-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2146_CR18","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s12149-022-01769-x","volume":"36","author":"E Imabayashi","year":"2022","unstructured":"Imabayashi E, Tamamura N, Yamaguchi Y, Kamitaka Y, Sakata M, Ishii K. Automated semi-quantitative amyloid PET analysis technique without MR images for alzheimer\u2019s disease. Ann Nucl Med. 2022;36(10):865\u201375. https:\/\/doi.org\/10.1007\/s12149-022-01769-x.","journal-title":"Ann Nucl Med"},{"issue":"8","key":"2146_CR19","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.2967\/jnumed.112.115006","volume":"54","author":"R Lundqvist","year":"2013","unstructured":"Lundqvist R, Lilja J, Thomas BA, L\u00f6tj\u00f6nen J, Villemagne VL, Rowe CC, et al. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J Nucl Med. 2013;54(8):1472\u20138. https:\/\/doi.org\/10.2967\/jnumed.112.115006.","journal-title":"J Nucl Med"},{"issue":"1","key":"2146_CR20","doi-asserted-by":"publisher","first-page":"9891","DOI":"10.1038\/s41598-023-36986-5","volume":"13","author":"HW Roh","year":"2023","unstructured":"Roh HW, Son SJ, Hong CH, Moon SY, Lee SM, Seo SW, et al. Comparison of automated quantification of amyloid deposition between PMOD and heuron. Sci Rep. 2023;13(1):9891. https:\/\/doi.org\/10.1038\/s41598-023-36986-5.","journal-title":"Sci Rep"},{"issue":"10","key":"2146_CR21","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvad\u00f3 G, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49(10):3508\u201328. https:\/\/doi.org\/10.1007\/s00259-022-05784-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"2146_CR22","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s12149-022-01792-y","volume":"36","author":"H Matsuda","year":"2022","unstructured":"Matsuda H, Okita K, Motoi Y, Mizuno T, Ikeda M, Sanjo N, et al. Clinical impact of amyloid PET using 18F-florbetapir in patients with cognitive impairment and suspected alzheimer\u2019s disease: a multicenter study. Ann Nucl Med. 2022;36(12):1039\u201349. https:\/\/doi.org\/10.1007\/s12149-022-01792-y.","journal-title":"Ann Nucl Med"},{"issue":"7","key":"2146_CR23","doi-asserted-by":"publisher","first-page":"e3092","DOI":"10.1002\/brb3.3092","volume":"13","author":"H Matsuda","year":"2023","unstructured":"Matsuda H, Soma T, Okita K, Shigemoto Y, Sato N. Development of software for measuring brain amyloid accumulation using 18 F-florbetapir PET and calculating global centiloid scale and regional Z-score values. Brain Behav. 2023;13(7):e3092. https:\/\/doi.org\/10.1002\/brb3.3092.","journal-title":"Brain Behav"},{"issue":"12","key":"2146_CR24","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","volume":"14","author":"M Navitsky","year":"2018","unstructured":"Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, et al. Standardization of amyloid quantitation with Florbetapir standardized uptake value ratios to the centiloid scale. Alzheimers Dement. 2018;14(12):1565\u201371. https:\/\/doi.org\/10.1016\/j.jalz.2018.06.1353.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"2146_CR25","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s12149-024-01919-3","volume":"38","author":"C Shang","year":"2024","unstructured":"Shang C, Sakurai K, Nihashi T, Arahata Y, Takeda A, Ishii K, et al. Comparison of consistency in centiloid scale among different analytical methods in amyloid PET: the CapAIBL, VIZCalc, and amyquant methods. Ann Nucl Med. 2024;38(6):460\u20137. https:\/\/doi.org\/10.1007\/s12149-024-01919-3.","journal-title":"Ann Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02146-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02146-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02146-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:36:51Z","timestamp":1774687011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02146-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2146"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02146-0","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments. This retrospective study was approved by the Ethics Committee of Tokushima University Hospital (Approval No. 4588).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement for written informed consent was waived in accordance with the institutional guidelines for retrospective studies using anonymized data, with appropriate information disclosure to the public.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"During the preparation of this manuscript, the authors used ChatGPT (OpenAI, San Francisco, CA, USA) to improve the clarity and grammar of the text. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the final version of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of AI-Assisted technologies"}}]}}